Get the Stockscreener App
6.68
1.76%
-0.12
Bioventus Inc stock is traded at $6.68, with a volume of 501.74K.
It is down -1.76% in the last 24 hours and down -15.97% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$6.80
Open:
$6.79
24h Volume:
501.74K
Relative Volume:
1.35
Market Cap:
$487.06M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-11.13
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
-8.99%
1M Performance:
-15.97%
6M Performance:
-43.49%
1Y Performance:
+22.34%
1-Day Range:
$6.655
$6.90
1-Week Range:
$6.02
$7.34
52-Week Range:
$5.25
$14.38
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.68 | 487.06M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Bioventus reiterates 2025 guidance with focus on growth and profitability - MSN
Barclays PLC Has $696,000 Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus (BVS) Price Target Trimmed by Craig-Hallum Analyst | BVS Stock News - GuruFocus
Bioventus Inc. (NASDAQ:BVS) Q1 2025 Earnings Call Transcript - Insider Monkey
Is Bioventus (NASDAQ:BVS) Using Too Much Debt? - simplywall.st
Bioventus First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures - Yahoo Finance
Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures By GuruFocus - Investing.com Canada
Bioventus Reports Q1 2025 Financial Performance - TipRanks
Bioventus: Q1 Earnings Snapshot - CTPost
Bioventus Earnings Call: Growth Amid Challenges - TipRanks
Financial Fitness Check: Examining Bioventus Inc (BVS)’s Key Ratios - DWinneX
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Bioventus Q1 2025 slides: 5% organic growth despite revenue decline, maintains guidance - Investing.com India
Earnings call transcript: Bioventus Q1 2025 beats EPS forecast but faces stock dip - Investing.com Nigeria
Bioventus Inc. Q1 Loss Narrows - Nasdaq
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Bioventus (BVS) Exceeds Q1 Revenue Expectations with Strong Perf - GuruFocus
Bioventus Inc Q1 2025 Earnings: Revenue Hits $123.9M, Beating Es - GuruFocus
Bioventus (BVS) Exceeds Q1 Revenue Expectations with Strong Performance | BVS Stock News - GuruFocus
Bioventus reports Q1 revenue and earnings above estimates, shares dip By Investing.com - Investing.com Nigeria
Bioventus reports Q1 revenue and earnings above estimates, shares dip - Investing.com Australia
Bioventus Reports First Quarter Financial Results | BVS Stock Ne - GuruFocus
Bioventus Reports First Quarter Financial Results - The Manila Times
Bioventus Reports First Quarter Financial Results | BVS Stock News - GuruFocus
Bioventus Inc. Reports Q1 2025 Financial Results: Revenue Decline of 4.3% but Organic Growth of 5.0% and Improved Non-GAAP EPS - Nasdaq
Bioventus Inc. SEC 10-Q Report - TradingView
(BVS) Trading Report - news.stocktradersdaily.com
Examining the Future: Bioventus's Earnings Outlook - Nasdaq
Bioventus Inc (BVS) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
Bioventus Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Legal & General Group Plc Raises Position in Bioventus Inc. (NYSE:BVS) - Defense World
Orthobiologics Market Growth Statistics & Future Prospects | Medtronic, Orthofix Medical, Bioventus - openPR.com
Bioventus Q1 2025 Earnings Preview: Key Metrics and Business Updates Coming May 6 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
LPL Financial LLC Has $433,000 Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Alliancebernstein L.P. Sells 3,500 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
SEC Form DEFA14A filed by Bioventus Inc. - Quantisnow
Bioventus Inc. (NASDAQ:BVS) On The Verge Of Breaking Even - Yahoo Finance
Bioventus SVP Katrina Church sells shares for $9,712 - Investing.com Australia
Bioventus CFO Singleton sells $29,333 in stock - Investing.com Australia
Bioventus SVP Katrina Church sells shares for $9,712 By Investing.com - Investing.com South Africa
Bioventus CFO Singleton sells $29,333 in stock By Investing.com - Investing.com South Africa
Bioventus SVP sells shares worth $22,392 By Investing.com - Investing.com India
Bioventus SVP sells shares worth $22,392 - Investing.com
Bioventus Executives Sell Shares to Cover Taxes - TradingView
Bioventus Inc. (NYSE:BVS) Shares Acquired by Vanguard Group Inc. - Defense World
KLP Kapitalforvaltning AS Acquires Shares of 7,100 Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus ($BVS) Is Paying a $15.2M Settlement to Investors — Here’s How to Get Your Share - TradingView
Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights - GlobeNewswire Inc.
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):